NCT00087776View on ClinicalTrials.gov

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

PHASE3TerminatedINTERVENTIONAL
Enrollment

393

Participants

Timeline

Start Date

December 6, 2002

Primary Completion Date

October 27, 2007

Study Completion Date

October 27, 2007

Conditions
Malignant Melanoma
Interventions
DRUG

Taxoprexin

Administered by intravenous infusion over 2 hour infusion on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course

DRUG

Dacarbazine

Administered by intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (three weeks) per course

Trial Locations (1)

19403

Luitpold Pharmaceuticals, Inc., Norristown

Sponsors
All Listed Sponsors
lead

American Regent, Inc.

INDUSTRY

NCT00087776 - Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter